前列腺癌新辅助雄激素抑制后PSA水平与长期结局的汇总分析
该研究汇总4项NRG Oncology/RTOG随机临床试验共2404例接受新辅助雄激素抑制(neoAS)后放疗联合同期短期雄激素抑制的前列腺癌患者,验证neoAS后、放疗前PSA水平与长期结局的关联。结果显示PSA>0.1 ng/mL组生化失败、局部失败、远处转移、病因特异性死亡和全因死亡风险均显著升高。
要点
- neoAS后、放疗前PSA>0.1 ng/mL与生化失败风险独立相关(HR 2.00,P<.0001)。
- PSA>0.1 ng/mL与局部失败风险独立相关(HR 2.33,P<.0001)。
- PSA>0.1 ng/mL与病因特异性死亡风险独立相关(HR 1.75,P=.03)。
核心结论
- neoAS后、放疗前PSA>0.1 ng/mL的患者临床结局劣于PSA≤0.1 ng/mL的患者。
- neoAS后、放疗前PSA水平相对于医疗照护连续过程中PSA水平的作用目前尚未定义,但可在未来临床试验中检验。
研究设计与样本
- 汇总分析纳入NRG Oncology/RTOG试验9202、9408、9413和9910共2404例前列腺癌患者。
- 患者接受放疗前neoAS及同期雄激素抑制(不放疗后雄激素抑制)。
- 采用多变量模型检验预设二分类的neoAS后、放疗前PSA水平(≤0.1 vs >0.1 ng/mL)与临床结局的关联。
主要发现
- 存活患者中位随访9.4年。
- neoAS后、放疗前PSA中位水平为0.3 ng/mL,32%的患者PSA≤0.1 ng/mL。
- 单因素分析中,PSA>0.1 ng/mL与生化失败风险升高相关(HR 2.04,P<.0001)。
- 单因素分析中,PSA>0.1 ng/mL与局部失败(HR 2.51,P<.0001)、远处转移(HR 1.73,P=.0006)、病因特异性死亡(HR 2.36,P<.0001)和全因死亡(HR 1.24,P=.005)风险升高相关。
- 多变量模型(纳入基线和治疗变量)中,PSA>0.1 ng/mL独立与生化失败(HR 2.00,P<.0001)、局部失败(HR 2.33,P<.0001)和病因特异性死亡(HR 1.75,P=.03)风险升高相关。
关键数值与推荐
- 预设二分类界值:neoAS后、放疗前PSA≤0.1 vs >0.1 ng/mL。
- 单因素分析中PSA>0.1 ng/mL的HR:生化失败2.04(P<.0001)、局部失败2.51(P<.0001)、远处转移1.73(P=.0006)、病因特异性死亡2.36(P<.0001)、全因死亡1.24(P=.005)。
- 多变量分析中PSA>0.1 ng/mL的HR:生化失败2.00(P<.0001)、局部失败2.33(P<.0001)、病因特异性死亡1.75(P=.03)。
临床怎么用
- 对于接受neoAS后放疗联合同期短期雄激素抑制的前列腺癌患者,放疗前PSA>0.1 ng/mL提示不良结局风险较高。
- neoAS后、放疗前PSA水平可作为风险分层参考,但其相对于医疗照护连续过程中PSA水平的作用尚未定义。
局限性
- neoAS后、放疗前PSA水平相对于医疗照护连续过程中PSA水平的作用目前尚未定义。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To validate whether prostate-specific antigen (PSA) level after neoadjuvant androgen suppression (neoAS) is associated with long-term outcome after neoAS and external beam radiation therapy (RT) with concurrent short-term androgen suppression (AS) in patients with prostate cancer. METHODS AND MATERIALS: This study included 2404 patients. The patients were treated with neoAS before RT and concurrent AS (without post-RT AS) and were pooled from NRG Oncology/RTOG trials 9202, 9408, 9413, and 9910. Multivariable models were used to test associations between the prespecified dichotomized post-neoAS, pre-RT PSA level (≤0.1 vs >0.1 ng/mL) groupings, and clinical outcomes. RESULTS: The median follow-up for surviving patients was 9.4 years. The median post-neoAS, pre-RT PSA level was 0.3 ng/mL, with 32% of patients having levels ≤0.1 ng/mL. Race, Gleason score, tumor stage, node stage, pretreatment PSA level, and duration of neoAS were associated with the groups of patients with PSA levels ≤0.1 and >0.1 ng/mL. In univariate analyses, post-neoAS, pre-RT PSA level >0.1 ng/mL was associated with increased risks of biochemical failure (hazard ratio [HR], 2.04; P < .0001); local failure (HR, 2.51; P < .0001); distant metastases (HR, 1.73; P = .0006); cause-specific mortality (HR, 2.36; P < .0001); and all-cause mortality (HR, 1.24; P = .005). In multivariable models that also included baseline and treatment variables, post-neoAS, pre-RT PSA level >0.1 ng/mL was independently associated with increased risk of biochemical failure (HR, 2.00; P < .0001); local failure (HR, 2.33; P < .0001); and cause-specific mortality (HR, 1.75; P = .03). CONCLUSIONS: Patients with a PSA level >0.1 ng/mL after neoAS and before the start of RT had less favorable clinical outcomes than patients whose PSA level was ≤0.1 ng/mL. The role of post-neoAS, pre-RT PSA level relative to PSA levels obtained along the continuum of medical care is not presently defined but could be tested in future clinical trials.
引用
- Hallemeier CL, Zhang P, Pisansky TM, et al. Prostate-Specific Antigen After Neoadjuvant Androgen Suppression in Prostate Cancer Patients Receiving Short-Term Androgen Suppression and External Beam Radiation Therapy: Pooled Analysis of Four NRG Oncology Radiation Therapy Oncology Group Randomized Clinical Trials. Int J Radiat Oncol Biol Phys. 2019. PMID: 30959123. doi:10.1016/j.ijrobp.2019.03.049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。